Cyclosporine Trough Level Monitoring

Archive of SID

Editor,

In an interesting paper, Hami and colleagues¹ mentioned cyclosporine trough level (C0) has no direct relation with drug side effects and it is not a suitable measure for assessment of drug side

effects. In addition, they concluded C0 is not a reliable tool for dose adjustment of drug after kidney transplantation. We would like to draw the attention of the readers to studies that might be relevant to discuss in this context.

Iranian Journal of Kidney Diseases | Volume 5 | Number 3 | May 2011



Archive of SID Letter

> We agree with Hami and colleague¹ that we need a reliable way to monitor cyclosporine therapy because adequate blood level of cyclosporine is required for prevention of the allograft rejection. Moreover, 2-hour postdose level of cyclosporine (C2) is also not a good predictive value for kidney allograft side effect. We recommend that other tools are required to approach to therapeutic drug monitoring in order to prevent kidney allograft rejection and cyclosporine nephrotoxicity. Several studies have been previously described the nonsignificant statistical link between C0 and C2 with kidney allograft function.²⁻⁴ However, some data suggest that C2 levels are correlated better with dose and serum creatinine concentration.⁵ Although a previous international consensus statement on C2 monitoring strategies suggests importance of C2 blood level,⁶ direct evidence for an advantage of C2 monitoring over C0 blood levels is limited.⁷ Furthermore, a pilot study shows no advantages of C2 monitoring.² We also previously showed a relatively good outcome in kidney transplants despite obvious lower levels of C2 compared with international consensus recommendations.8 Pourfarziani and associates demonstrated that although most of the patients had C2 levels lower than the suggested ranges, they observed acceptable patient and graft survival rates. They suggested that different ethnic populations might need different target levels definition.⁹ Furthermore, approaching specific C2 levels for kidney transplant patients with different immunosuppressant regimen or genetic polymorphisms seem necessary.

> On the other hand, cyclosporine blood level may lead to some clinical problems; for example, blood samples for C2 levels are taken during a more dynamic phase of cyclosporine absorption than those for trough levels, accurate timing of samples is a point of question.¹⁰ Controversial questions of C0 and C2 levels induced immunosuppressive action based upon close observation of most recent pharmacodynamic approaches are still interesting. Instead of a priori not beneficial cyclosporine monitoring tools, it seemed to be logical that we should re-inspect the possible of using them as

a supplementary tool towards better therapeutic drug monitoring of cyclosporine or it needs to reevaluate and find new target for therapeutic plan in kidney transplant patients.

Behzad Einollahi, Mojtaba Teimoori

Nephrology and Urology Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran E-mail: einollahi@inju.ir

REFERENCES

- Hami M, Mojahedi MJ, Naghibi M, Shakeri MT, Sharifipour F. Cyclosporine trough levels and its side effects in kidney transplant recipients. Iran J Kidney Dis. 2010;4:153-7.
- Kyllonen LE, Salmela KT. Early cyclosporine C0 and C2 monitoring in de novo kidney transplant patients: a prospective randomized single-center pilot study. Transplantation. 2006;81:1010-5.
- Ferraresso M, Ghio L, Edefonti A, Vigano S, Boschiero L, Berardinelli L. C0 or C2 driven cyclosporine monitoring in long-term pediatric kidney transplant recipients: is there any threat for chronic rejection development? Pediatr Transplant. 2005;9:328-31.
- Cantarovich M, Giannetti N, Cecere R. Impact of cyclosporine 2-h level and mycophenolate mofetil dose on clinical outcomes in de novo heart transplant patients receiving anti-thymocyte globulin induction. Clin Transplant. 2003;17:144-50.
- Kalyoncu M, Topaloglu R, Bayrakci U, et al. Cyclosporine drug monitoring with C0 and C2 concentrations in children with stable renal allograft function. Pediatr Transplant. 2006;10:168-71.
- Levy G, Thervet E, Lake J, Uchida K. Patient management by Neoral C(2) monitoring: an international consensus statement. Transplantation. 2002;73:S12-8.
- Campbell SB, Johnson DW. Patient management by cyclosporine C2 monitoring: not enough science yet to justify the practice. Transplantation. 2003;75:1917-8.
- Einollahi B, Taheri S, Lessan-Pezeshki M, et al. Approach to a target value for 2-hours post dose cyclosporine (C2) during the first week post renal transplantation. Ann Transplant. 2009;14:18-22.
- Pourfarziani V, Nemati E, Taheri S, Khoddami-Vishte HR, Azizabadi Farahani M. Satisfactory outcome despite low 2-hour postdose cyclosporine level in Iranian kidney recipients. Iran J Kidney Dis. 2008;2:99-101.
- Saint-Marcoux F, Rousseau A, Le Meur Y, et al. Influence of sampling-time error on cyclosporine measurements nominally at 2 hours after administration. Clin Chem. 2003;49:813-5.